Votrient – Treatment for Renal Cell Cancer and Soft Tissue Sarcoma

1
Votrient Treatment for Renal Cell Cancer and
Soft Tissue Sarcoma
2
Generic Pazopanib Brand Votrient Votrient
manufactured by GlaxoSmithKline was approved by
FDA for renal cell cancer (RCC) treatment. And
in 2012, Votrient obtained an additional approval
from FDA for second indication, i.e. it can now
be administered to patients who have received
chemotherapy and have a certain subtypes of Soft
Tissue Sarcoma (STS).
3
According to a study PISCES which does the
comparison of Pazopanib (Brand Votrient) and
Sunitinib (Brand Sutent) in the treatment of
metastatic renal cell carcinoma. And the
results were very optimistic for Pazopanib, as
the study showed that nearly 70 of patients
preferred Votrient over Sunitinib and Sunitinib
was far behind Pazopanib with 22. Pazopanib /
Votrient cost information
4
Renal cell cancer and soft tissue sarcoma Renal
Cell Cancer (RCC) is one of the type of Kidney
Cancer which affects the inner lining of the
kidney. Renal cancer is generally seen in adult
men aged between 50 to 60 years. This type of
disease can easily spread to to Lungs and other
organs of the body. The most common form of
treatment for small tumours is Surgery and
Thermal ablation. With more of targeted
therapies developing like Votrient, theses
medications are gaining acceptance as these
medications are effective results in the clinical
trials.
5
Being an aggressive form of cancer, Soft Tissue
Sarcoma affects the connective tissues of the
body. With up to 20 types of STS found which
can affect the human body and if left untreated
they will continue to affect the body and will
start to affect other parts of the body including
bones and lungs. According to the estimation
done by National Cancer Institute there were
reported 11000 cases of STS in 2011 in the US
alone, and among them approximately 4000 died.
6
Pazopanib mechanism of action Votrient is a type
of targeted therapy that contains multityrosine
kinase inhibitor of the VEGF (vascular
endothelial growth factor) receptor. Blocking
the growth of tumour cells is the main function
of this drug. It blocks the proteins and other
targets within the cell like tyrosine kinases
which are located on the surface of tumour cells.
And both proteins and target cells are reason
for new production of blood vessels in the cancer
cells and angiogenesis. And with Pazopanib
working, it blocks these targets which in turn
helps to destroy cancer cells.
7
Clinical trials of votrient on patients with
RCC The VEG102616 trial which is a study on
advanced RCC which comes under Phase 2, tested
the efficacy and safety of Votrient. In the Phase
2 trial, a total of 255 patients were recruited
and they demonstrated an overall response rate of
35. And the results of Phase 2 trial also
supported the trials done in Phase 3. Phase 3
trials results also established the efficacy and
safety on use of Votrient. In he Phase 3 of
trial, a total of 435 patients were recruited
with metastatic or / and Advanced renal cell
cancer (RCC).
8
There was also another trial conducted, namely
VEG105192 which compared the placebo and
Votrient, taking progression free survival (PFS)
as the primary end points. The median PFS was 4.2
months in case of placebo and it was 5 more
months than placebo i.e. 9.2 months. The second
phase of phase 3 trial named COMPARZ which
involves comparing the safety, efficacy and
tolerability of Pazopanib as compared to
Sunitinib will be carried out in July 2012. A
total of 1053 patients have been recruited for
this phase which will last till second half of
2012.
9
Study of votrient for the treatment of STS Phase
3 PALETTE was the main basis used for granting
approval of Votrient. This phase basically
explored in soft tissue sarcoma. This trial
recruited 369 patients wo were suffering from
metastatic soft tissue sarcoma and had already
received chemotherapy treatment. In this phase,
the results were compared with placebo. It
established that Votrient was significantly more
effective than placebo, by improving PFS in
recruited patients. The median in case of
Votrient was 4.6 months as compared to median of
1.6 months with placebo.
10
"Votrient was effective in significantly
improving PFS in patients, compared to
placebo. Sunitinib has been marked as the
standard for RCC treatment because it was one of
the very first to establish itself in the
market. With the results from the PISCES study,
Votrient has become a clear preference amongst
patients with RCC. And with ongoing trend, it is
estimated that Votrient will overpower sunitinib
with 49 of market share by 2016.
11

• Some analyst had predicted that due to the lack
  of clinical data, comparison of Votrient with
  other drugs which comes under same category as
  Pazopanib, may turn to be a disadvantageous for
  Votrient.
• But this disadvantage can be overturned with the
  ongoing COMPARZ study. And this study will help
  in establishing efficacy of Votrient in the
  market.
• Pazopanib / Votrient comes in the following
  dosages
• Generic Pazopanib / Brand Votrient 200 mg tablet
• Generic Pazopanib / Brand Votrient 400 mg tablet

12
Pazopanib cost information The information
provided on the page is meant for the purpose of
being helpful and educational. It should not be
considered as medical advice.     Votrient,
pazopanib, votrient cost, pazopanib cost,
pazopanib mechanism of action, pazopanib sarcoma,
generic Votrient, votrient 400 mg, Votrient 200 mg
13
Contact Us Website www.CancerCurePharmacy.com E
mail CustomerCare_at_CancerCurePharmacy.com